Valeant Gets Lender Deal to Waive Default, Loosen Debt Terms


Valeant Pharmaceuticals International Inc. won the support of its lenders to waive a default and ease some restrictions on its loan pact as the drugmaker seeks to rein in its $32 billion debt load. The company expects to close the amendment and waiver next week, according to a statement on Thursday.



from Biotech News